|
|
|
|
GenericsWeb exposes differences between Abatacept generic launch contraints in EU and US
Apotex in pole position for first launch of generic Zymar (Gatifloxacin)?Sydney, Australia, February 18, 2010 - GenericsWeb, the leader in pharmaceutical patent analysis and searching, has recently published an article based on its proprietary Pipeline...
|
|
|
Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423
In extensive-stage small cell lung cancer (SCLC), the combination of pemetrexed plus carboplatin has shown activity and appeared to be well-tolerated.We conducted a trial to confirm the efficacy and to assess the tolerability of this chemotherapy combination...
|
|
|
Astra buys arthritis drug
LONDON/BANGALORE (Reuters) - AstraZeneca Plc waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals Inc's next-generation drug R788 for up to $1.245 billion.The deal is a big vote of confidence in the...
|
|
|
Rigel to Host Conference Call Today to Discuss Its Partnership With AstraZeneca on Fostamatinib Disodium (R788
SOUTH SAN FRANCISCO, Calif., Feb.16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL) announced that its senior management team will host a conference call, and simultaneous audio webcast, today at 8:30 a.m. EST (5:30 a.m. PST) to...
|
|
|
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- F
AstraZeneca and Rigel Pharmaceuticals have announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and...
|
|
|
Week Of Feb. 15, 2010: Company And People Notes: Abbott Completes Acquisition Of Solvay; Merck Names President Of Consumer Healthcare; And More.
ePT--the Electronic Newsletter of Pharmaceutical Technology Company Notes Abbott Laboratories (Abbott Park, IL) completed its acquisition of Solvay Pharmaceuticals (Belgium) for EUR $4.5 billion ($6.2 billion).Abbott expects the acquisition to add...
|
|
|
Week Of Feb. 15, 2010: Company And People Notes: Abbott Completes Acquisition Of Solvay; Merck Names President Of Consumer Healthcare; And More.
ePT--the Electronic Newsletter of Pharmaceutical Technology Company Notes Abbott Laboratories (Abbott Park, IL) completed its acquisition of Solvay Pharmaceuticals (Belgium) for EUR $4.5 billion ($6.2 billion).Abbott expects the acquisition to add...
|
|
|
Week Of Feb. 15, 2010: Company And People Notes: Abbott Completes Acquisition Of Solvay; Merck Names President Of Consumer Healthcare; And More.
ePT--the Electronic Newsletter of Pharmaceutical Technology Company Notes Abbott Laboratories (Abbott Park, IL) completed its acquisition of Solvay Pharmaceuticals (Belgium) for EUR $4.5 billion ($6.2 billion).Abbott expects the acquisition to add...
|
|
|
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- F
SOUTH SAN FRANCISCO, Calif., Feb.16 (HSMN NewsFeed) -- AstraZeneca and Rigel Pharmaceuticals (Nasdaq:RIGL ) today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel...
|
|
|
Apotex in pole position for first launch of generic Zymar (Gatifloxacin)
- GenericsWeb, the leader in pharmaceutical patent analysis and searching, has recently published an article based on its proprietary Pipeline Patent Intelligence to reveal a number of patents that could further delay generic versions of Gatifloxacin beyond...
|
|
|
Drug makers sign agreement to develop rheumatoid arthritis drug
SOUTH SAN FRANCISCO,Calif.(Feb. 17) Anglo-Swedish drug maker AstraZeneca and American drug maker Rigel Pharmaceuticals have signed a global licensing agreement to develop and commercialize an investigational drug for rheumatoid arthritis, the two announced...
|
|
|
Rigel Investors Balk at AstraZeneca Deal
They're unable to focus on the overall payout, and seem stuck on lower-than-expected upfront payment.Share this article: A- A A+ Medical Device Makers Brace for Change Hospitality Sector Sees Brighter Days Ahead Five Investing Myths Debunked Playing...
|
|
|
AstraZeneca to pay Rigel up to $1.25 billion in arthritis pact
LONDON (MarketWatch) -- AstraZeneca on Tuesday said it's reached a pact to pay Rigel Pharmaceuticals up to $1.25 billion before royalties to license a drug used to treat rheumatoid arthritis.AstraZeneca /quotes/comstock/13*!azn/quotes/nls/azn (AZN 43.93, 0...
|
|
|
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage ...
AstraZeneca and Rigel Pharmaceuticals announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and...
|
|
|
AstraZeneca and Rigel Pharmaceuticals sign licensing agreement
(Datamonitor via COMTEX) -- AstraZeneca and Rigel Pharmaceuticals have signed an exclusive worldwide licensing agreement for the global development and commercialization of fostamatinib disodium, the company's late-stage investigational product for...
|
|
|
AstraZeneca and Rigel Pharmaceuticals sign licensing agreement - ...
AstraZeneca and Rigel Pharmaceuticals have signed an exclusive worldwide licensing agreement for the global development and commercialization of fostamatinib disodium, the company's late-stage investigational product for rheumatoid arthritis, or RA, and...
|
|
|
AstraZeneca Leaps for Rigel's Arthritis Drug
AstraZeneca has announced an exclusive worldwide licence agreement for access to the global development and commercialisation of Rigel's fostamatinib disodium, an investigational product for rheumatoid arthritis (RA) and additional indications.
|
|
|
AstraZeneca Initially Pays $100M for Rigels Late-Stage RA Drug
Rigel Pharmaceuticalswill earn $100 million up front as part of an exclusive, global agreement with AstraZeneca covering the late-stage rheumatoid arthritis (RA) candidate R788 (fostamatinib disodium).The deal gives AstraZeneca exclusive rights to...
|
|
|
News and FDA Updates for Alkermes (NASDAQ:ALKS), Rigel (Nasdaq:RIGL), Baxter (NYSE:BAX)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
BiomedReports: News and FDA Updates for Alkermes (NASDAQ:ALKS), Rigel (Nasdaq:RIGL), Baxter (NYSE:BAX)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
AstraZeneca signs deal with Rigel on RA treatment
AstraZeneca is looking to enter the lucrative rheumatoid arthritis market by in-licensing a phase II treatment.The global market for rheumatoid arthritis treatment is now worth $13bn, having grown from $1.3bn in 1998, thanks the arrival of new medicines such...
|
|
|
AstraZeneca and Rigel Pharmaceuticals sign licensing agreement
AstraZeneca and Rigel Pharmaceuticals have signed an exclusive worldwide licensing agreement for the global development and commercialization of fostamatinib disodium, the company's late-stage investigational product for rheumatoid arthritis, or RA, and...
|
|
|
AstraZeneca seals $1bn deal for RA drug
AstraZeneca will commercialize a Rheumatoid Arthritis product being developed by USA's Rigel Pharmaceuticals.AstraZeneca, listed on London Stock Exchange said the deal with Nasdaq listed Rigel's late-stage investigational product for rheumatoid arthritis (RA...
|
|
|
AstraZeneca, Rigel Pharma sign worldwide licensing pact to develop & commercialise fostamatinib disodium
_ AstraZeneca, Rigel Pharma sign worldwide licensing pact to develop & commercialise fostamatinib disodium.
|
|
|
Rigel Investors Balk at AstraZeneca Deal
Stocks mentioned in this article AstraZeneca ADR representing 1 Ord Shs (AZN) Stock Quote, Chart, News, Add to Watchlist Rigel Pharmaceuticals Inc (RIGL) Stock Quote, Chart, News, Add to Watchlist Teva Pharmaceutical Industries ADR Reptg One Ord Shs (TEVA)...
|
